Eevia Health Plc, ("Eevia" or "The Company"), has received a sales order from its Australian distributor Ingredients Plus. Ingredients Plus serves leading nutraceutical brands in Oceania and Asia with high-quality ingredients. The end customer is a major natural health company based out of Sydney, Australia selling its products across Asia and Oceania.
The sales value of this order is c. 223 000 EUR, and the product is Feno-Myrtillus® bilberry extract standardized with 36% anthocyanins. The order is in line with expectations for repeat sales of this product going forward.
The Feno-Myrtillus® powder is extracted from arctic bilberries and has a high concentration of anthocyanins, a polyphenol with great benefits to human health.
Seinäjoki, Finland 09.06.2022
For further information, please contact:
Stein Ulve, CEO, Eevia Health Plc Gabriella Beni, CFO, Eevia Health Plc
Email: firstname.lastname@example.org email@example.com
Telephone: +358 400 22 5967 +358 407 48 8666
Eevia Health Plc, founded in March 2017, addresses significant health problems with bioactive compounds extracted from plant materials. The materials are primarily wild harvested from the pristine Finnish and Swedish forests near or above the Arctic Circle. The extracts are sold B2B as ingredients to dietary supplements and food brands globally. These global brands utilize the ingredients in their consumer product formulas.
Eevia Health is a manufacturer of 100% organically certified plant extracts. Although a significant product; Elderberry extract, is made from cultivated berries, most of Eevia's other raw materials, such as bilberry, lingonberry, Chaga-mushroom, and pine bark, are wild-harvested in a sustainable fashion.
Eevia Health operates a modern green-chemistry production facility in Finland. The factory operates near the raw material harvest areas. A uniquely short value chain enables an environmentally friendly carbon footprint, competitive pricing, and extreme transparency. Eevia listed its shares at Spotlight Stock Market in Sweden in June 2021, with the short name EEVIA.
To learn more, please visit www.eeviahealth.com or follow Eevia Health on LinkedIn @EeviaHealth.
The Board of Directors of Eevia Health Plc ("Eevia" or the "Company") has today decided on a rights issue with preferential rights for Eevia's existing shareholders ("Rights Issue"). The target amount is approximately SEK 21.6 million. The proceeds shall primarily finance sales and marketing efforts and increase working capital. About 82 percent of the Rights Issue is covered by subscription and guarantee commitments.
Following a successful quality audit by Eevia Health Plc's ("Eevia" or "The Company") French auditor Natural Ingredients, Eevia has received an 85 KEUR sales order for Bilberry extract from its distributor.
Eevia Health Plc, ("Eevia" or "The Company"), has received a 20 KEUR sales order from a new Finnish customer.
Eevia Health Plc, ("Eevia" or "The Company"), has received a 96 KEUR sales order from a European nutraceutical brand owner.
Eevia Health Plc ("Eevia" or "The Company") is welcoming Dr. Tommi Kilpeläinen asits new Scientific Product Manager.
The Extraordinary General Meeting of Shareholders of Eevia Health Plc, corp. reg. no 2825194-4 (the "Company") was held on October 11, 2022 in Seinäjoki, Finland, whereby the shareholders primarily resolved the following matters:
Authorizing the Board of Directors to decide on the issuance of shares, options, and other special rights
Notice is given to the shareholders of Eevia Health Abp (Plc) to the Extraordinary General Meeting to be held on 11 October 2022 at 12:00 (Finnish time GMT +3) at the main office of Eevia Health Abp in Koulukatu 14, Seinäjoki, Finland.
The reception of persons who have registered for the meeting and the distribution of voting tickets will commence at 11:00.
Eevia Health Plc, ("Eevia" or "The Company"), has received two small starting sales orders from South Korea and Taiwan, totaling approx. 24 KEUR for organically certified bilberry extracts.
Eevia Health Plc ("Eevia" or "The Company") is releasing its quarterly financial report for the second quarter of 2022.
Eevia Health Plc ("Eevia" or "The Company") is welcoming Tuomas Jylhä as interim Chief Financial Officer. Gabriella Beni has decided to leave the Company for personal reasons to focus on private matters. Eevia wishes her the very best in her future endeavors. Tuomas Jylhä will take over the position on July 26th.